Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Investor Presentation (January 2026)
28 slides from Neurizon Therapeutics's investor presentation, Jan 15, 2026
Slide 1: Investor webinar presentation
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Investor webinar presentation 15 January 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative tre
Slide 2: Neurizon Shareholder Webinar: Funding, Execution and Path Forward
For personal use only Neurizon Shareholder Webinar “Funding, Execution and Path Forward” Dr Michael Thurn, Managing Director & Chief Executive Officer January 2026 ABN 35 094 006 023
Slide 3: Disclaimer
Disclaimer For personal use only This disclaimer applies to this presentation and the information contained in it (This presentation has been Future Matters prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective in
Slide 4: Our Vision
For personal use only Our Vision To lead the development of neurodegenerative treatments towards a promising new horizon for patients.
Slide 5: Our Promise
Accelerating Patient Driving Hope and Access to Clinical For personal use only Innovative ALS Our Promise Treatment Progress Unlocking the potential Delivering commercial of Neurizon to address readiness and high unmet need in stakeholder neurodegenerative value diseases
Slide 6: Corporate Overview
Corporate Overview Mid-stage biotechnology company targeting human neurodegenerative diseases Share Price Performance Capital Structure (AUD$) 9 January 2026 For personal use only Closing Price (AUD$) Volume (m) Current Share Price (NUZ/NUZOA) $0.82/ $0.012 0.50 6 52 Week Low / High (NUZ) $0. 079/$0
Slide 7: Our Strategic Progress
Our Strategic Progress Focus remains on advancing ALS clinical program by commencing enrolment in the HEALEY ALS Platform Trial (Phase 2/3) For personal use only Drug / Approved/ Next Major Partnerships & Licensing Indication Preclinical Phase 1 Phase 2 Phase 3 Dosage Form Marketed Catalysts Acceler
Slide 8: Demonstrating Meaningful Progress: FY 2026 Milestones
Demonstrating Meaningful Progress: FY 2026 Milestones For personal use only Executed NUZ-001 IND First Preliminary Australian Global License Opened, clearing registration R&D Funding Patent granted Agreement the path to batch of received for NUZ-001 – with Elanco HEALEY NUZ-001 Expiry 2041 JP Morgan
Slide 9: Entering The Next Phase Of Value Creation: HEALEY ALS Platform Trial
For personal use only Entering The Next Phase Of Value Creation: HEALEY ALS Platform Trial
Slide 10: HEALEY ALS Platform Trial
HEALEY ALS Platform Trial NUZ-001 cleared for entry into the HEALEY ALS Platform Trial HEALEY ALS Platform Trial is a competitive process led by a group of expert ALS scientists and members of the Healey Science Advisory Committee For personal use only HEALEY ALS Platform Trial Design Innovative Tri
Slide 11: HEALEY ALS Platform Trial Regimen 'I' for NUZ-001
HEALEY ALS Platform Trial Regimen ‘I’ for NUZ-001 36-week Double blind Placebo 36-week Active Treatment Screening Period Controlled Period Extension Period For personal use only NUZ-001 10 mg/kg Biomarkers DNA ALSFRS-R 3:1 Randomization NUZ-001 n=160 patients 10 mg/kg Placebo Primary Endpoint • Chan
Slide 12: Regimen-I HEALEY ALS Platform Trial Expected Key Milestones
‘Regimen-I’ HEALEY ALS Platform Trial Expected Key Milestones IND Amendment Submission Q4 2025 Platform Trial IND submitted to regulatory authorities For personal use only FDA Clearance FDA cleared NUZ-001 entry accepted Q4 2025 NUZ-001 for entry into HEALEY ALS Platform Q1 2026 3 First Patient Scre
Slide 13: Regulatory and Market Update
For personal use only Regulatory and Market Update
Slide 14: Fast Track Designation – Regulatory Context and Program Continuity
Fast Track Designation – Regulatory Context and Program Continuity Regulatory guidance received with clinical execution proceeding as planned For personal use only What This Means for NUZ ALS Program Development and Execution Remain on Track Fast Track Designation Status Fast Track Designation is a
Slide 15: Accelerated & Streamlined Path to NDA and Launch
Accelerated & Streamlined Path to NDA and Launch Elanco License Agreement For personal use only Sample 1 • Strengthens NDA readiness MODULE 1 Elanco License • Reduces development cost Text Admin Agreement • Supports accelerated timeline & launch readiness Sample 2 MODULE 2 • Comprehensive non- • Com
Slide 16: Major Pharma Investment Validates ALS Commercial Opportunity
Major Pharma Investment Validates ALS Commercial Opportunity Shionogi transaction represents a meaningful external validation of the ALS market and improves the strategic, commercial, and partnering backdrop for Neurizon’s NUZ-001 program For personal use only • USD $2.5B deal validates ALS market •
Slide 17: Strategic Funding
For personal use only Strategic Funding
Slide 18: HEALEY Funding Strategy
HEALEY Funding Strategy Focused on flexibly and efficiently securing adequate funding for the HEALEY ALS Platform Trial Neurizon’s strategy is to efficiently secure adequate funding for the HEALEY ALS Platform Trial, to enable the Company to commit to it1. The strategy is focused on protecting share
Slide 19: Offer Overview
Offer Overview Offer Structure Up to ~A$24.2 million via the issue of up to ~303.5 million new fully paid ordinary shares in the Company (“New Shares”) comprising: • an ~A$7.1 million placement via the issue of ~89.2 million New Shares to certain eligible institutional, sophisticated or For personal
Slide 20: Timetable
Timetable1 Trading Halt Friday, 19 December 2025 Trading Halt Lifted and Return to Trading on the ASX, Announce Results of Placement, Announce Entitlement For personal use only Tuesday, 23 December 2025 Offer Entitlement Offer ‘Ex’ Date Monday, 29 December 2025 Entitlement Offer Record Date Tuesday,
Slide 21: Upcoming Milestones
For personal use only Upcoming Milestones
Slide 22: Near-Term Milestones and Objectives
Near-Term Milestones Objectives For personal use only ✓ HEALEY ALS Platform Trial– IRB Approval ✓44 th J.P. Morgan Annual Healthcare Conference and other events • Preclinical Updates • Australian R&D Refund (net of R&D funding) • HEALEY Updates • Preclinical Updates • Liquid Formulation PK Study Ini
Slide 23: Registration now open!
Registration now open! https://www.fiercebiotech.com/premium/we binar/1375715 For personal use only Shareholder Webinar January 2026 22
Slide 24: NUZ-001: Orphan Drug Designated Small Molecule Showing Promising Survival Trends in ALS
NUZ-001: Orphan Drug Designated Small Molecule Showing Promising Survival Trends in ALS Well-characterised Drug Current ALS Treatments ✓ ✓ For personal use only • First-in-class small molecule • High unmet need for disease modifying • Validated blood brain barrier treatment penetration • Limited eff
Slide 25: Thank You
For personal use only THANK YOU Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com
Slide 26: Appendix - International Offer Restrictions
For personal use only Appendix 1 - International Offer Restrictions
Slide 27: International Offer Restrictions
International Offer Restrictions This presentation does not constitute an offer of New Shares of the Company in any jurisdiction in which it would be unlawful. In particular, this presentation may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside
Slide 28: International Offer Restrictions
International Offer Restrictions United Kingdom Neither this presentation nor any other presentation relating to the offer has been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Market
Neurizon Therapeutics — Investor Presentation (January 2026) on 6ix